论文部分内容阅读
目的了解树突状细胞(DC)疫苗对淋巴瘤荷瘤鼠的免疫治疗作用及疫苗免疫对淋巴瘤细胞攻击的免疫保护效应。方法将小鼠淋巴瘤A20细胞接种BAL B/c小鼠,建立荷瘤鼠模型,分别接种Id-DC和CPP-Id-DC疫苗,观察荷瘤鼠肿瘤大小变化及生存时间。小鼠预先分别接种Id-DC和PP-Id-DC疫苗,然后以A20细胞攻击,观察其成瘤率及生存时间。均注射PBS作为对照。结果接种PBS的荷瘤鼠肿瘤生长快,中位生存时间为33.4 d;接种Id-DC的荷瘤鼠,个别小鼠肿瘤生长减慢,中位生存时间为40.4 d,与PBS对照组相比,差异无统计学意义;而接种CPP-Id-DC的荷瘤鼠肿瘤生长明显减慢,5只小鼠中,1只肿瘤停止生长,1只肿瘤逐渐缩小、消退,90 d内的中位生存时间为70.8 d,明显长于PBS对照组和Id-DC接种组(P<0.01)。以Id-DC预防接种的小鼠予A20细胞攻击后大部分成瘤(4/5),成瘤时间为7～12 d,较PBS对照组略延长,中位生存时间为44.8 d;CPP-Id-DC接种组小鼠60 d内均无肿瘤生长。结论CPP-Id负载的DC疫苗治疗B细胞淋巴瘤优于单纯Id负载的DC疫苗,可以提高抑瘤率和延长荷瘤鼠的生存时间,可在小鼠体内产生对A20淋巴瘤细胞攻击的免疫保护。
Objective To investigate the immunotherapeutic effect of dendritic cell (DC) vaccine on lymphoma-bearing mice and the immunoprotective effect of vaccine immunization on lymphoma cells. Methods BALB / c mice were inoculated with mouse lymphoma A20 cells. The tumor-bearing mice model was established. The vaccines of Id-DC and CPP-Id-DC were inoculated respectively and the tumor size and survival time were observed. The mice were inoculated with Id-DC and PP-Id-DC vaccine in advance and then challenged with A20 cells to observe the tumorigenic rate and survival time. All mice were injected with PBS as a control. Results The tumor-bearing mice inoculated with PBS grew rapidly and the median survival time was 33.4 days. In the tumor-bearing mice vaccinated with Id-DC, the tumor growth of individual mice was slowed down and the median survival time was 40.4 days. Compared with the PBS control group , While the difference was not statistically significant. However, the tumor growth of tumor-bearing mice inoculated with CPP-Id-DC was significantly slowed down. One of the five mice stopped growing and one tumor gradually reduced and disappeared. The median of 90 days The survival time was 70.8 days, which was significantly longer than PBS control group and Id-DC inoculation group (P <0.01). The mice inoculated with Id-DC had most of the tumorigenicity (4/5) after A20 cell challenge. The tumorigenic time was 7-12 days, slightly longer than PBS control group, with a median survival time of 44.8 days. CPP- There was no tumor growth within 60 days in Id-DC vaccinated mice. CONCLUSION: DC vaccines loaded with CPP-Id are superior to DC vaccines with Id alone in increasing the tumor inhibition rate and prolonging the survival time of tumor-bearing mice, and can result in immune-challenged A20 lymphoma cells in mice protection.